NEW YORK (GenomeWeb News) — Critical Therapeutics today said Beckman Coulter has exercised a licensing option to continue using its high mobility group box 1 technology.
 
CT said the companies penned a licensing deal in 2005 that gave BC the use of HMGB1 to develop an immunoassay to detect inflammatory diseases. HMGB1 has been identified as a possible mediator of tissue damage caused by inflammation.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.